PFIZER WKN: 852009 ISIN: US7170811035 Forum: Aktien Thema: Hauptdiskussion

Amis sind seeeeehr aufgeregt im US Forum

Dachte mir schon, da ist was am laufen, Buffet wartet schon

https://www.change.org/p/pfizer-board-of-directors-pfizer-stock-manipulation?redirect=false

Es gibt sogar eine P e t i t i o n

Es gibt sogar eine Petition

Bourla sold 132,508 Pfizer (PFE) shares at a price of $41.94, according to a filing with the Securities and Exchange Commission. That works out to proceeds of nearly $5.6 million.

Seit dem Bourla und Buffet die Aktien verkauft haben geht es nur in den Keller.... Wird der Kurs jetzt gedrückt, dass die wieder einsteigen können?

https://www.investors.com/news/technology/pfizer-stock-buy-now/

Hab gerade eben gelesen

Technical Analysis: PFE Stock Isn't Forming A Base Pfizer stock isn't currently forming a definitive chart pattern. Shares briefly broke out on Nov. 9 after shares topped a buy point at 39.55 out of a flat base. But Pfizer stock later fell as much as 9.4% below that entry on Nov. 17. That triggered a sell rule when shares tumble 7%-8% below their entries. As of the Feb. 7 close, shares were below their 50-day and 200-day moving averages. (Related: Keep tabs on chart patterns by visiting IBD's MarketSmith.com.) Shares of Pfizer have a poor IBD Composite Rating of 26. The 1-99 measure pits a stock's key growth measures against all other stocks. Leading stocks tend to have CRs of 95 or better, according to IBD Digital. Pfizer stock also has a weak IBD Relative Strength Rating of 3 out of a best-possible 99. The RS Rating measures a stock's 12-month running performance against all other stocks. That RS Rating means Pfizer stock tops just 3% of all stocks in terms of performance. The pharmaceutical company's EPS Rating, a measure of profitability, is a 69 out of a best-possible 99. The EPS Rating compares a stock's recent and longer-term earnings growth against all other stocks. So, Is Pfizer Stock A Buy Right Now? Based on CAN SLIM rules of investing, PFE stock isn't a buy right now. Shares briefly topped a buy point out of a flat base on Nov. 9, but couldn't hold onto their gain. It's best to buy a stock when it's within 5% above a buy point. Pfizer stock also isn't forming a new base. Further, the pharmaceutical company is expected to report growth in the first quarter, but sales growth won't be bullish enough to line up with CAN SLIM advice.

Mein ek liegt bei 28,90, falls es weiter sinkt, wovon ich nicht ausgehe, lege ich noch was nach....

El gesenkt auf 28,80 EUR. Liegen lassen bis Sommer und mal wieder draufschauen

..... nachgekauft. Pfizer ist für mich eine sehr sichere Bank.

https://www.fool.com/investing/2021/02/11/3-reasons-pfizers-failures-could-lead-to-a-big-acq/

Weil es 230Mio Biontech-Aktien und 5,5Mrd Pfizer-Aktien gibt.

Nachkaufen so ne stabile Firma.. checke aber nicht wh der Wert hier 28€ ist und Biontech 96€ obwohl Pfizer viel Wertvoller ist Martkkap.?